Search - tctmd.com

Displaying 401 - 420 of 510

Sort: Relevancy | Date

News Industry News

New Data Evaluating The Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Demonstrate 94.4 Percent Primary Patency Rate At Nine Months

April 28, 2015

News Conference News ACC 2015

Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease

L.A. McKeown

March 15, 2015

News Daily News

含可生物降解聚合物的 DES 可安全使用、耐用长达 5 年

L.A. McKeown

January 28, 2015

News Daily News

Los SLF con Polímero Biodegradable son Seguros y Duraderos al cabo de 5 Años

L.A. McKeown

January 28, 2015

News Daily News

DES With Biodegradable Polymer Safe, Durable Through 5 Years

L.A. McKeown

January 28, 2015

News Daily News

CABG, DES Yield Similar Outcomes in Isolated Proximal LAD Disease

Todd Neale

December 22, 2014

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Daily News

Debut of DES Failed to Alter Survival Benefit of CABG vs PCI in Multivessel Disease

L.A. McKeown

November 06, 2014

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Bo Xu

September 16, 2014

Presentation TCT 2014

Case Study: DES in a High Bleeding Risk Patient with Complex Coronary Artery Disease

Presenter: Philip M. Urban, Marco Valgimigli, Christian M. Spaulding, Robert A. Byrne

September 14, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

September 13, 2014

News Daily News

Nationwide Registry Shows Trends in DES Use Over a Decade

June 02, 2014

News Conference News EuroPCR 2014

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

Caitlin E. Cox

May 28, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Improvements in Revascularization Reduce Cardiac Death, MI and Repeat Revascularization, but not All-Cause Mortality in Japan

Caitlin E. Cox

March 20, 2014

News Daily News

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Caitlin E. Cox

March 13, 2014

News Daily News

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Yael L. Maxwell

February 26, 2014

Advertisement

New Data Evaluating The Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Demonstrate 94.4 Percent Primary Patency Rate At Nine Months

Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease

含可生物降解聚合物的 DES 可安全使用、耐用长达 5 年

Los SLF con Polímero Biodegradable son Seguros y Duraderos al cabo de 5 Años

DES With Biodegradable Polymer Safe, Durable Through 5 Years

CABG, DES Yield Similar Outcomes in Isolated Proximal LAD Disease

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

Debut of DES Failed to Alter Survival Benefit of CABG vs PCI in Multivessel Disease

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Case Study: DES in a High Bleeding Risk Patient with Complex Coronary Artery Disease

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Misago BMS Performs Well in Multinational Trial of Patients with SFA Lesions

Nationwide Registry Shows Trends in DES Use Over a Decade

EuroPCR 2014: Clinical Challenges, Novel Innovations Share the Limelight

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Improvements in Revascularization Reduce Cardiac Death, MI and Repeat Revascularization, but not All-Cause Mortality in Japan

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Drug-Eluting Balloons Reduce Restenosis, TLR in Diabetic Patients with CLI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content